Abstract
According to the classification presented by Lehmann BD (2016), triple-negative breast cancer (TNBC) is a heterogeneous group of malignant tumors with four specific subtypes: basal-like (subtype 1 and subtype 2), mesenchymal, and luminal androgen receptor (LAR) subtypes. The basal-like subtypes of carcinomas predominate in this group, accounting for up to 80% of all cases. Despite the significantly lower proportions of mesenchymal and LAR variants in the group of breast carcinomas with a TNBC profile, such tumors are characterized by aggressive biological behavior. To this end, the LAR subtype is of particular interest, since the literature on such tumors presents different and even contradictory data concerning the disease course and prognosis. This review is devoted to the analysis of the relevant literature, reflecting the main results of studies on the molecular properties and clinical features of the disease course of LAR-type TNBC carcinomas.
摘要
根据Lehmann BD (2016) 分类, 三阴性乳腺癌 (TNBC) 是一组异质性恶性肿瘤, 存在4种特定的亚型: 基底样亚型 (亚型1和亚型2) 、间充质亚型和腔内雄激素受体 (LAR) 亚型。基底样亚型癌在TNBC中占主导地位, 约占所有病例的80%。虽然在TNBC患者中, 间充质亚型和LAR亚型占比显著较低, 但此类肿瘤同样具有侵袭性生物学行为。有关LAR亚型的文献研究在患者病程与预后方面存在明显的争议; 为此, 本文集中关注LAR亚型, 通过对相关文献进行分析, 重点展示了LAR型TNBC病程中能够体现其分子特性与临床特征的研究结果。
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abd El-Rehim DM, Pinder SE, Paish CE, et al., 2004. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol, 203(2):661–671. https://doi.org/10.1002/path.1559
Ali AM, Ansari JAK, Abd El-Aziz NM, et al., 2017. Triple negative breast cancer: a tale of two decades. Anticancer Agents Med Chem, 17(4):491–499. https://doi.org/10.2174/1871520616666160725112335
Anestis A, Zoi I, Papavassiliou AG, et al., 2020. Androgen receptor in breast cancer—clinical and preclinical research insights. Molecules, 25(2):358. https://doi.org/10.3390/molecules25020358
Asano Y, Kashiwagi S, Onoda N, et al., 2016. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. Br J Cancer, 114(1): 14–20. https://doi.org/10.1038/bjc.2015.434
Asghar US, Barr AR, Cutts R, et al., 2017. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res, 23(18):5561–5572. https://doi.org/10.1158/1078-0432.CCR-17-0369
Astvatsaturyan K, Yue Y, Walts AE, et al., 2018. Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features. PLoS ONE, 13(6):e0197827. https://doi.org/10.1371/journal.pone.0197827
Balkenhol MCA, Vreuls W, Wauters CAP, et al., 2020. Histological subtypes in triple negative breast cancer are associated with specific information on survival. Ann Diagn Pathol, 46:151490. https://doi.org/10.1016/j.anndiagpath.2020.151490
Bareche Y, Venet D, Ignatiadis M, et al., 2018. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol, 29(4): 895–902. https://doi.org/10.1093/annonc/mdy024
Barton VN, Christenson JL, Gordon MA, et al., 2017. Androgen receptor supports an anchorage-independent, cancer stem cell-like population in triple-negative breast cancer. Cancer Res, 77(13):3455–3466. https://doi.org/10.1158/0008-5472.CAN-16-3240
Bhattacharya R, Banerjee K, Mukherjee N, et al., 2017. From molecular insight to therapeutic strategy: the holistic approach for treating triple negative breast cancer. Pathol Res Pract, 213(3): 177–182. https://doi.org/10.1016/j.prp.2017.01.001
Bhattarai S, Saini G, Gogineni K, et al., 2020. Quadruple-negative breast cancer: novel implications for a new disease. Breast Cancer Res, 22:127. https://doi.org/10.1186/s13058-020-01369-5
Bonnefoi H, Grellety T, Tredan O, et al., 2016. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol, 27(5):812–818. https://doi.org/10.1093/annonc/mdw067
Borri F, Granaglia A, 2021. Pathology of triple negative breast cancer. Semin Cancer Biol, 72:136–145. https://doi.org/10.1016/j.semcancer.2020.06.005
Bozovic-Spasojevic I, Zardavas D, Brohée S, et al., 2017. The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data. Clin Cancer Res, 23(11):2702–2712. https://doi.org/10.1158/1078-0432.CCR-16-0979
Burstein MD, Tsimelzon A, Poage GM, et al., 2015. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res, 21(7):1688–1698. https://doi.org/10.1158/1078-0432.CCR-14-0432
Camorani S, Crescenzi E, Gramanzini M, et al., 2017. Aptamermediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers. Sci Rep, 7:46659. https://doi.org/10.1038/srep46659
Chalakur-Ramireddy NKR, Pakala SB, 2018. Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer. Biosci Rep, 38(1):BSR20171357. https://doi.org/10.1042/BSR20171357
Choi JE, Kang SH, Lee SJ, et al., 2015. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol, 22(1):82–89. https://doi.org/10.1245/s10434-014-3984-z
Collina F, Aquino G, Brogna M, et al., 2019. LncRNA HOTAIR up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast Cancer. J Cancer, 10(9):2018–2024. https://doi.org/10.7150/jca.29670
Dieci MV, Tsvetkova V, Griguolo G, et al., 2019. Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: analysis of 263 patients treated with standard therapy for stage I-III disease. Front Oncol, 9:452. https://doi.org/10.3389/fonc.2019.00452
Ding YC, Steele L, Warden C, et al., 2019. Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity. Oncotarget, 10(2):198–208. https://doi.org/10.18632/oncotarget.26559
Echavarria I, López-Tarruella S, Picornell A, et al., 2018. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification. Clin Cancer Res, 24(8):1845–1852. https://doi.org/10.1158/1078-0432.CCR-17-1912
Elfgen C, Varga Z, Reeve K, et al., 2019. The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay. Breast Cancer Res Treat, 177: 67–75. https://doi.org/10.1007/s10549-019-05298-6
Gerratana L, Basile D, Buono G, et al., 2018. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev, 68:102–110. https://doi.org/10.1016/j.ctrv.2018.06.005
Gucalp A, Tolaney S, Isakoff SJ, et al., 2013. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res, 19(19):5505–5512. https://doi.org/10.1158/1078-0432.CCR-12-3327
Guestini F, McNamara KM, Ishida T, et al., 2016. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification. Expert Opin Ther Targets, 20(6):705–720. https://doi.org/10.1517/14728222.2016.1125469
Hennigs A, Riedel F, Gondos A, et al., 2016. Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study. BMC Cancer, 16:734. https://doi.org/10.1186/s12885-016-2766-3
Hill BS, Sarnella A, Capasso D, et al., 2019. Therapeutic potential of a novel αvβ3 antagonist to hamper the aggressiveness of mesenchymal triple negative breast cancer sub-type. Cancers (Basel), 11(2):139. https://doi.org/10.3390/cancers11020139
Hon JDC, Singh B, Sahin A, et al., 2016. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res, 6(9):1864–1872.
Honma N, Ogata H, Yamada A, et al., 2021. Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women. Hum Pathol, 111:10–20. https://doi.org/10.1016/j.humpath.2021.01.005
Jia HY, Truica CI, Wang B, et al., 2017. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist Updat, 32:1–15. https://doi.org/10.1016/j.drup.2017.07.002
Jiang YZ, Ma D, Suo C, et al., 2019. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell, 35(3):428–440.E5. https://doi.org/10.1016/j.ccell.2019.02.001
Kensler KH, Regan MM, Heng YJ, et al., 2019. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98. Breast Cancer Res, 21:30. https://doi.org/10.1186/s13058-019-1118-z
Kim S, Moon BI, Lim W, et al., 2018. Feasibility of classification of triple negative breast cancer by immunohistochemical surrogate markers. Clin Breast Cancer, 18(5): E1123–E1132. https://doi.org/10.1016/j.clbc.2018.03.012
Kono M, Fujii T, Lim B, et al., 2017. Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review. JAMA Oncol, 3(9):1266–1273. https://doi.org/10.1001/jamaoncol.2016.4975
Kumar S, Bal A, Das A, et al., 2021. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer. Breast Cancer Res Treat, 187(3):625–633. https://doi.org/10.1007/s10549-021-06242-3
le Du F, Eckhardt BL, Lim B, et al., 2015. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget, 6(15):12890–12908. https://doi.org/10.18632/oncotarget.3849
Lehmann BD, Bauer JA, Chen X, et al., 2011. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 121(7):2750–2767. https://doi.org/10.1172/JCI45014
Lehmann BD, Jovanović B, Chen X, et al., 2016. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE, 11(6):e0157368. https://doi.org/10.1371/journal.pone.0157368
Li D, Lai WJ, Wang QS, et al., 2021. CD151 enrichment in exosomes of luminal androgen receptor breast cancer cell line contributes to cell invasion. Biochimie, 189:65–75. https://doi.org/10.1016/j.biochi.2021.06.007
Li JW, Li N, Jiang YZ, et al., 2020. Ultrasonographic appearance of triple-negative invasive breast carcinoma is associated with novel molecular subtypes based on transcriptomic analysis. Ann Transl Med, 8(7):435. https://doi.org/10.21037/atm.2020.03.204
Li SP, Li XY, Yang SQ, et al., 2021. Proteomic landscape of exosomes reveals the functional contributions of CD151 in triple-negative breast cancer. Mol Cell Proteomics, 20: 100121. https://doi.org/10.1016/j.mcpro.2021.100121
Liu YR, Jiang YZ, Xu XE, et al., 2016. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res, 18:33. https://doi.org/10.1186/s13058-016-0690-8
Marra A, Trapani D, Viale G, et al., 2020. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer, 6:54. https://doi.org/10.1038/s41523-020-00197-2
Nielsen TO, Hsu FD, Jensen K, et al., 2004. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10(16):5367–5374. https://doi.org/10.1158/1078-0432.CCR-04-0220
Pareja F, Geyer FC, Marchiò C, et al., 2016. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer, 2:16036. https://doi.org/10.1038/npjbcancer.2016.36
Perou CM, Sørlie T, Eisen MB, et al., 2000. Molecular portraits of human breast tumours. Nature, 406(6797):747–752. https://doi.org/10.1038/35021093
Pietri E, Conteduca V, Andreis D, et al., 2016. Androgen receptor signaling pathways as a target for breast cancer treatment. Endocr Relat Cancer, 23(10):R485–R498. https://doi.org/10.1530/ERC-16-0190
Santonja A, Sánchez-Muñoz A, Lluch A, et al., 2018. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget, 9(41):26406–26416. https://doi.org/10.18632/oncotarget.25413
Traina TA, Miller K, Yardley DA, et al., 2015. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). J Clin Oncol, 33(15 Suppl):1003. https://doi.org/10.1200/jco.2015.33.15_suppl.1003
Traina TA, Miller K, Yardley DA, et al., 2018. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol, 36(9):884–890. https://doi.org/10.1200/JCO.2016.71.3495
Vidula N, Yau C, Wolf D, et al., 2019. Androgen receptor gene expression in primary breast cancer. NPJ Breast Cancer, 5:47. https://doi.org/10.1038/s41523-019-0142-6
Wagenblast E, Soto M, Gutiérrez-Ángel S, et al., 2015. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature, 520(7547): 358–362. https://doi.org/10.1038/nature14403
Wang CJ, Pan B, Zhu HJ, et al., 2016. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget, 7(29):46482–46491. https://doi.org/10.18632/oncotarget.10208
Xu M, Yuan Y, Yan PJ, et al., 2020. Prognostic significance of androgen receptor expression in triple negative breast cancer: a systematic review and meta-analysis. Clin Breast Cancer, 20(4):E385–E396. https://doi.org/10.1016/j.clbc.2020.01.002
Author information
Authors and Affiliations
Corresponding author
Additional information
Author contributions
Sergey VTORUSHIN determined the topic of article, carried out the study design and article revision. Anastasia DULESOVA collected the literature. Nadezhda KRAKHMAL collected the literature, wrote the article, and guided the article. All authors have read and approved the final manuscript, and therefore, have full access to all the data in the study and take responsibility for the integrity and security of the data.
Compliance with ethics guidelines
Sergey VTORUSHIN, Anastasia DULESOVA, and Nadezhda KRAKHMAL declare that they have no conflict of interest.
This article does not contain any studies with human or animal subjects performed by any of the authors.
Rights and permissions
About this article
Cite this article
Vtorushin, S., Dulesova, A. & Krakhmal, N. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features. J. Zhejiang Univ. Sci. B 23, 617–624 (2022). https://doi.org/10.1631/jzus.B2200113
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B2200113
Key words
- Luminal androgen receptor (LAR) subtype
- Triple-negative breast cancer (TNBC)
- Androgen receptor (AR)
- Prognosis